May 28, 2026

@michaelokun

A new randomized Tourette syndrome medication study just dropped on Ecopipam. Spoiler alert: It targeted D1 dopamine receptors and not D2 receptors and weight gain, sedation and movements were all less. Randomized means participants were assigned by chance. Dopamine D1 receptor antagonist means the medication blocks a specific dopamine signaling pathway that may contribute to tics. Gilbert and colleagues describe in a new paper in JAMA Neurology how Ecopipam, a selective dopamine D1 receptor antagonist, performed in a phase 3 randomized clinical trial for Tourette syndrome. Key points: – Ecopipam reduced the risk of tic relapse by about 50% compared to placebo in children and adolescents w/ Tourette syndrome. – Benefits in tic severity were maintained for up to 24 weeks in many participants who initially responded to treatment. – The medication did not show clinically meaningful weight gain, metabolic complications or drug induced movement disorders which are frequent concerns w/ many currently used tic medications. My take: Tourette syndrome treatment needs more options. Many currently available medications can help tics, however side effects including weight gain, sedation and movement complications and these frequently limit long term use. This study is important because it targets dopamine differently through the D1 receptor rather than the more traditional D2 pathway. The results are encouraging though we still need longer term real world data and additional adult studies. Here are 5 points that resonated w/ me: 1- This is one of the more promising Tourette syndrome medication studies we have seen in years. 2- Targeting dopamine D1 receptors may offer a new therapeutic strategy beyond traditional antipsychotic medications. 3- The absence of major metabolic and movement related side effects could become a major advantage if findings hold up over time. 4- Tic disorders are frequently accompanied by anxiety, OCD and ADHD, so tolerability matters for families and health care providers. 5- The future of Tourette syndrome care will likely include more personalized approaches matched to the biology and symptom profile of each individual. https://cutt.ly/ItM8r7aX